eligibility_summary
Eligible adults with inoperable, advanced/metastatic gastric, GEJ, or esophageal adenocarcinoma, measurable disease per RECIST v1.1, ECOG PS 0–1, HER2-negative (IHC 0/1+ or FISH−), PD-L1 status known or tumor tissue available for testing. Excludes prior systemic therapy for locally advanced/unresectable/metastatic disease and significant intercurrent lung illnesses per protocol.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions and mechanisms: • ABBV-400: intravenous antibody–drug conjugate (ADC) targeting MET (c‑Met/HGFR) on tumor cells, upon internalization releases a cytotoxic topoisomerase I–inhibitor payload causing DNA damage and cell death. • Budigalimab (ABBV‑181): intravenous anti–PD‑1 monoclonal antibody (immune checkpoint inhibitor) that blocks PD‑1 to restore antitumor T‑cell activity. • Fluorouracil (5‑FU): antimetabolite that inhibits thymidylate synthase and incorporates into RNA/DNA. • Leucovorin (folinic acid): reduced folate that stabilizes the 5‑FU–thymidylate synthase complex, enhancing 5‑FU efficacy. • Oxaliplatin: platinum DNA crosslinker causing apoptosis. Cells/pathways targeted: • MET-expressing gastric/GEJ/esophageal adenocarcinoma cells (MET signaling). • PD‑1/PD‑L1 axis on T cells/tumor microenvironment. • Thymidylate synthase–dependent DNA synthesis in proliferating tumor cells. • DNA crosslink/repair pathways via platinum-induced damage.